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http://dxObjective: The aim of the present study was to identify the modern surgical results of pathologic T3 lung cancer
and to examine the heterogeneity of this group from the nationwide database.
Methods: The registered data of 11,663 cases from the Japanese Joint Committee of Lung Cancer Registry con-
ducted in 2010 were analyzed, which included patients with resected lung cancer during 2004. Of these patients,
531 with invasive T3 lung cancer constituted the study population.
Results: Of the 531 patients, 466 were men and 65 women, with a mean age of 65.9 years. The 3- and 5-year
survival rates and median survival timewas 54.0%, 44.9%, and 46 months, respectively. Amultivariate analysis
showed incomplete resection, N2 disease, and no adjuvant therapy were independent prognostic factors of a poor
outcome. However, pneumonectomy and N1 disease were not significantly associated with the prognosis. In
terms of each involved structure, we detected 407 patients with T3 tumors involving the chest wall, 56 involving
the mediastinal pleura, 45 with involvement of the bronchus within 2 cm of the carina, 31 involving the dia-
phragm, and 20 involving the pericardium. The corresponding 5-year survival rates were 43.2%, 40.1%,
55.2%, 42.6%, and 54.2%.
Conclusions: The modern 5-year survival rates of patients with T3 lung cancer involving any neighboring struc-
tures have been 40% to 55%, and the current pT3 group was proved to have a relatively uniform prognosis.
(J Thorac Cardiovasc Surg 2012;144:431-7)G
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The Journal of Thoracic and Canationwide retrospective registry study of primary lung can-
cer conducted by the Japanese Joint Committee of
Lung Cancer Registry in 2010, there were 1013 combined
resections (8.7%) with neighboring structures in 2004,
although the number was smaller than that in 1999
(n ¼ 1480 [11.1%]).1
The TNM staging system for lung cancer was revised and
promulgated in 2009; however, the distribution of involved
organs for the staging between T3 and T4 remained un-
changed.2 T3 lung cancers with limited, circumscribed ex-
trapulmonary extension are considered to be potentially
resectable, and the efficacy of surgical treatment for T3 le-
sions is generally accepted. However, the surgical results
for such advanced tumors have not been satisfactory, and
there has been heterogeneity in the reported prognoses de-
pending on the structure involved.3 The aim of the present
study was to identify the modern surgical results of patho-
logic T3 lung cancer with involvement of neighboring
structures, to examine the heterogeneity of this group
from the nationwide database, and to discuss the direction
of surgical resection for locally advanced lung cancer.METHODS
A nationwide retrospective registry study of patients with primary lung
cancer who underwent surgery from January 1, 2004, to December 31,rdiovascular Surgery c Volume 144, Number 2 431
TABLE 1. Patient characteristics
Variable Value
Age (y)
Mean 65.9
Range 37-83
Gender
Male 466 (87.8)
Female 65 (12.2)
Histologic type
Squamous cell carcinoma 250 (47.1)
Adenocarcinoma 201 (37.9)
Large cell carcinoma 45 (8.5)
Adenosquamous carcinoma 15 (2.8)
Other 20 (3.8)
Surgical procedure
Lobectomy 430 (81.0)
Pneumonectomy 63 (11.9)
Other 38 (7.1)
Residual tumor
R0 461 (86.8)
R1 48 (9.0)
R2 16 (3.0)
Rx 6 (1.1)
Nodal status
N0 351 (66.1)
N1 81 (15.3)
N2 98 (18.5)
N3 1 (0.2)
Induction therapy
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S2004, was performed by the Japanese Joint Committee of Lung Cancer Reg-
istry in 2010. The committee received the registries of 11,663 cases from
253 teaching hospitals in Japan. The data included the clinicopathologic pro-
files and prognoses, which had been described previously.1 The information
regarding the TNM classification was converted to the 7th edition of
the International Union Against Cancer-TNM staging system published in
2009.2 The histologic tumor type was described according to the World
Health Organization.4
The present study focused on pathologically confirmed invasive T3 lung
cancer involving the chest wall, mediastinal pleura, bronchus within 2 cm
of the carina, diaphragm, or pericardium. Ineligible patients, such as those
who underwent exploratory thoracotomy (n¼ 6), had small cell carcinoma
histologic features (n ¼ 13), low-grade malignant histologic features
(n ¼ 7), or distant metastasis (n ¼ 22), were excluded from the present
study. Superior sulcus tumors, defined as those with first rib involvement
in this registry study, were not extracted from the cohort when they were
categorized pathologically as T3 according to the TNM staging system
(n¼ 10). Therefore, 531 cases were enrolled in the present study, with a fol-
low-up period of at least 5 years after surgery.
The survival time was measured from the date of surgery to the date
of death or the last follow-up examination. The survival curves were
estimated using the Kaplan-Meier method, and the differences in sur-
vival were assessed using the log-rank test. A multivariate analysis
for prognostic factors was performed using the Cox proportional haz-
ard model.
This registry followed the ethical guidelines for epidemiologic studies
published jointly by the Japan Ministry of Science, Culture, and Education
and the JapanMinistry of Health, Labor, andWelfare on June 17, 2002, and
revised August 16, 2007. In addition, the institutional review board of
Osaka UniversityMedical Hospital, where the registry office is located, ap-
proved the study, after the discussions published August 13, 2009 (approval
no. 09124). All statistical analyses were performed independently by the
biologic statistician (E.M.).
Yes 89 (16.8)
No 442 (83.2)
Adjuvant chemotherapy
Yes 177 (33.4)
No 323 (60.8)
Unknown 31 (5.8)
Involved structure
Chest wall 407 (76.6)
Mediastinal pleura 56 (10.6)
Bronchus 45 (8.5)
Diaphragm 31 (5.8)
Pericardium 20 (3.8)
Data presented as numbers, with percentages in parentheses.RESULTS
The characteristics of the 531 included patients with in-
vasive T3 lung cancer are listed in Table 1. Of the 531 pa-
tients, 466 were men and 65 were women, with a mean
age of 65.9 years (range, 37-83). In terms of tumor histo-
logic type, squamous cell carcinoma was the most com-
mon, followed by adenocarcinoma. From the pathologic
examinations, 461 patients (86.8%) underwent complete
resection of the lung and involved structures. Of all cases,
34% were pathologically confirmed as lymph node-
positive. Induction therapy was performed in 89 cases
(16.8%), including 46 cases of chemoradiotherapy, 35 of
chemotherapy, and 8 of radiotherapy. Adjuvant chemo-
therapy was administered to 177 patients, intravenously
in 110, orally in 57, and by other routes in 10. No data
were available on postoperative radiotherapy. Stratified
by the involved structures, the chest wall (including pari-
etal pleura only) was the most common, present in up to
76.6% of cases, followed by the mediastinal pleura
(10.6%), bronchus (8.5%), diaphragm (5.8%), and peri-
cardium (3.8%).
The overall survival curve for all 531 patients with inva-
sive T3 lung cancer is shown in Figure 1. The 3- and 5-year
overall survival rate after surgery was 54.0% and 44.9%,
respectively, and the median survival time was 46 months.432 The Journal of Thoracic and Cardiovascular SurgThe surgical mortality rate within 30 days postoperatively
was 1.1%, and the total in-hospital death rate was 3.2%.
Survival according to various factors in the patients with in-
vasive T3 lung cancer is detailed in Table 2. No significant
differences were seen in survival between the men and
women, those with squamous cell carcinoma versus adeno-
carcinoma, nor in those who underwent lobectomy versus
pneumonectomy (P ¼ .078). A pathologically complete re-
section (R0) resulted in markedly better survival than an in-
complete resection (R1þR2; Figure 2, A; P<.001). When
stratified by nodal status, the 351 patients with N0 disease
and 81 with N1 disease had a significantly better prognosis
than the 98 with N2 disease (5-year survival rate; 50.6%
and 46.3% vs 22.0%, P<.001 and P¼ .002, respectively).ery c August 2012
TABLE 2. Survival rates according to each factor
Variable
3-y
survival
(%)
5-y
survival
(%)
MST
(mo)
P
value
Gender NS
Male 53.6 44.7 45
Female 57.5 46.2 53
Histologic type NS
Squamous cell
carcinoma
52.6 45.5 43
Adenocarcinoma 58.6 45.1 50
Other 47.0 41.8 27
Surgical procedure NS
Lobectomy 55.3 46.2 50
Pneumonectomy 44.5 35.4 27
Other 56.2 46.4 41
Residual tumor <.001
R0 57.8 47.5 54
R1þR2 26.1 24.2 19
Nodal status NS*;<.001y; .002z
N0 60.6 50.6 62
N1 53.3 46.4 49
N2 30.3 22.0 21
Induction therapy NS
Yes 56.4 50.0 60
No 53.6 43.8 44
Adjuvant chemotherapy .006
Yes 62.8 51.8 62
No 49.1 41.1 35
MST, Median survival time; NS, no significance. *N0 vs N1. yN0 vs N2. zN1 vs N2.
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FIGURE 1. Overall survival curve for patients with invasive T3 lung can-
cer; 3- and 5-year survival rates and median survival time was 54.0%,
44.9%, and 46 months, respectively.
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N0 and N1 disease (P ¼ .436, Figure 2, B). When stratified
by perioperative therapy, adjuvant chemotherapy proved to
be a significant prognostic factor (P ¼ .006, Figure 2, C),
but induction therapy was not (P¼ .409). Multivariate anal-
ysis showed incomplete resection, N2 disease, and no
adjuvant therapy to be independent prognostic factors for
a poor outcome, but pneumonectomy and N1 disease
were not significantly associated with the prognosis
(Table 3).
The 3- and 5-year survival rates with the median survival
time of patients with lung cancer involving each structure
are listed in Table 4. Patients with bronchial invasion had
a better prognosis than those with the involvement of other
structures. Of the patients with T3 cancer and chest wall in-
vasion, those with N0 disease tended to have better survival
than thosewith N1 disease (P¼ .055) and had a significantly
better survival than those with N2 disease (P<.001). How-
ever, no significant difference was seen in survival between
patients with N1 and N2 disease (P ¼ .144; Figure 3). The
5-year survival rate of those with N2 disease involving the
mediastinal pleura was only 9.8%, significantly poorer
than the survival of those with N0 and N1 (P ¼ .026 and
P ¼ .001, respectively).
Only 1 patient died during the 5 years after surgery
among the 19 patients with bronchial invasion and without
lymph node involvement. However, no significant differ-
ence was seen in survival between those with N1 and N2
disease (P ¼ .594). For the patients with T3 disease and di-
aphragmatic invasion, the 5-year survival rate of those with
N0 was 55.0%, comparable to that of the patients with N0
disease and chest wall or pericardial involvement.The Journal of Thoracic and CaNevertheless, the survival of those with N1 and N2 disease
was much poorer than that of those with N0 disease (N0 vs
N1, P ¼ .044; N0 vs N2, P ¼ .031, respectively), although
only a few patients had nodal involvement. Patients with
pericardial invasion were the most infrequently found in
the present series, and their prognosis was relatively good
despite the positive nodal status.
Additional analyses were done concerning the prognosis
of patients with T3 disease and chest wall invasion. Of the
299 patients with N0 disease, 264 (88.3%) underwent
complete resection with no residual tumor after pathologic
examination. Of these, 119 patients had invasion only to
the parietal pleura and 145 had substantial chest wall in-
volvement. Their survival curves are presented in
Figure 4. No significant difference was seen in survival be-
tween those with shallow versus deep invasion, with
a 5-year survival rate of 50.6% and 48.7%, respectively
(P ¼ .702). In addition, extrapleural resection was per-
formed in 82 cases and en bloc chest wall resection in
22 cases for T3N0 lung cancer invading only the parietal
pleura. No significant difference was seen in survival ac-
cording to the extent of chest wall resection for patients
with shallow invasion to the chest wall (P ¼ .733,
Figure 5).rdiovascular Surgery c Volume 144, Number 2 433
Survival Function
Years
543210
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
R0
R1+R2
Survival Function
Years
543210
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
N0
N1
N2
Survival Function
Years
543210
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
Adjuvant (+)
Adjuvant (-)
FIGURE 2. Overall survival curves according to (A) residual tumor, (B) nodal status, and (C) use of adjuvant therapy in patients with invasive T3 lung
cancer. A, Complete resection resulted in markedly better survival than incomplete resection (P<.001). B, 351 N0 and 81 N1 patients had a significantly
better prognosis than the 98 N2 patients (5-year survival, 50.6% and 46.3% vs 22.0%; P ¼ .000 and P ¼ .002, respectively), and no significant difference
was seen between the N0 and N1 patients (P ¼ .436). C, Adjuvant chemotherapy was proved to be a significant prognostic factor (P ¼ .006).
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SDISCUSSION
A number of reports have been published concerning the
surgical results for invasive T3 lung cancers from several in-
stitutions. However, they have often included consecutive
cases over a long period, and the outcomes were somewhat
nebulous.3,5,6 The present study reports on surgical cases
treated within 1 year and followed up for more than 5
years. In addition, the present study evaluated T3 tumors
according to the involved sites, in contrast to the
International Association for the Study of Lung CancerTABLE 3. Multivariate analysis of prognostic factors in patients with
invasive T3 lung cancer
Variable Reference HR
95%
CI
P
value
Surgical procedure
(pneumonectomy)
Other procedures 0.863 0.584-1.275 .459
Residual tumor
(R1þR2)
R0 2.007 1.432-2.814 <.001
Nodal status (N1) N0 1.156 0.790-1.692 .455
Nodal status (N2) N0 2.212 1.636-2.991 <.001
Adjuvant
chemotherapy (yes)
No 0.575 0.439-0.753 <.001
HR, Hazard ratio; CI, confidence interval.
434 The Journal of Thoracic and Cardiovascular Surgstaging project, which did not.7 Therefore, the present study
provides accurate modern surgical results of a large number
of cases and the prognosis stratified by each involved struc-
ture from the nationwide database.
Complete resection and lymph nodemetastasis have been
reported as implicit prognostic factors for patients with lo-
cally advanced lung cancer, and our results have also con-
firmed this trend. However, it was surprising that no
significant difference was seen in survival between patients
with T3N0 and T3N1 tumors (P¼ .436), and the 5-year sur-
vival rate of the latter group was 46.4%. This relatively
good outcome seems to have been because many of the
T3N1 tumors infiltrating central structures such as the me-
diastinal pleura, main bronchus, or pericardium contributed
to the favorable prognosis.
The common belief that ‘‘pneumonectomy is a disease’’
was not proved to be true in the present cohort.8,9
Multivariate analysis showed that the surgical procedures
used for lung resection were not a significant prognostic
factor, although T3 lung cancer involving various structures
were included in the present analysis. Although 26 patients
had bronchial invasion less than 2 cm from the carina, these
patients were not a majority in the pneumonectomy group.
Recent series have shown the feasibility of pneumonectomyery c August 2012
TABLE 4. Survival rates according to each structure
Involved
structure
Patients
(n)
3-y survival
(%)
5-y survival
(%)
MST
(mo)
Chest wall
All 407 51.6 43.2 42
N0 299 58.3 49.1 60
N1 43 42.3 36.5 28
N2 65 27.3 20.5 20
Mediastinal pleura
All 56 56.7 40.1 46
N0 23 62.6 37.9 46
N1 13 84.6 76.2 NR
N2 19 26.0 9.8 21
Bronchus
All 45 64.4 55.2 NR
N0 12 100 91.7 NR
N1 22 54.6 45.5 45
N2 11 45.5 36.4 31
Diaphragm
All 31 49.7 42.6 35
N0 20 65.0 55.0 65
N1 3 0 0 10
N2 8 18.8 18.8 11
Pericardium
All 20 54.2 54.2 63
N0 8 50.0 50.0 13
N1 5 80.0 80.0 NR
N2 7 38.1 38.1 31
MST, Median survival time, NR, not reached.
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FIGURE 4. Overall survival curves according to depth of invasion in pa-
tients with completely resected T3N0 lung cancer involving the chest wall.
No statistically significant difference was observed in survival between the
2 groups (P ¼ .702).
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findings of the present study are thus considered to follow
the modern consensus that ‘‘pneumonectomy is feasible forSurvival Function
Years
543210
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
N0
N1
N2
FIGURE 3. Overall survival curves according to nodal status for patients
with lung cancer involving the chest wall. Patients with N0 disease tended
to have better survival than those with N1 disease (P¼ .055), and they also
had significantly preferable survival compared with those with N2 disease
(P<.001).
The Journal of Thoracic and Caselected cases.’’10 It is suspected that the improvements in an-
esthesiology and perioperative care and strict patient selec-
tion resulted in the better survival of patients who
underwent extended resection.
Regarding perioperative therapies, adjuvant chemother-
apy has been proved to be effective for whole stage II and
IIIA cases.11,12 In the present study, adjuvant chemotherapy
was also effective when targeted toward T3 disease.
However, detailed information, such as the indications,
chemotherapy regimen, dose intensity, and so forth, wereSurvival Function
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FIGURE 5. Overall survival curves according to extent of combined re-
section in patients with completely resected T3N0 lung cancer involving
the parietal pleura. No significant difference was seen in survival according
to extent of chest wall resection (P ¼ .733).
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advocated the usefulness of adjuvant radiotherapy for
invasive T3 tumors.6,13 However, information on
radiotherapy was not collected in the present registry study.
Induction therapy followed by surgery has become
a standard strategy for superior sulcus tumors; however,
only a few reports have been published on its use for other
T3 tumors.14,15 Therefore, additional investigation of the
individual tumor types will be needed in the future.
The chest wall is the most common site infiltrated by pe-
ripheral lung cancer. A number of investigators have de-
scribed the prognostic factors of the disease.16,17
However, it is still controversial whether the depth of
invasion or the extent of combined resection influences
patient survival.16,17 Patients with the chest wall invasion
underwent complete resection and had N0 disease, and we
found no statistically significant differences according to
the depth of the tumor invasion with respect to survival.
In addition, among patients with tumor invasion only to
the parietal pleura, extrapleural resection and en bloc
chest wall resection resulted in similar survival rates.
Doddoli and colleagues6 demonstrated that en bloc resec-
tion was associated with a significantly better prognosis
from the viewpoint of safety margins for patients with inva-
sion limited to the parietal pleura. In contrast, some inves-
tigators have recommended extrapleural resection for
patients with invasion limited to the parietal pleura because
of the lower mortality or morbidity rates.18,19 In the present
study, extrapleural resection was generally selected for lung
cancer with shallow invasion, and the results have shown
that experienced surgeons made the correct judgment
regarding the extent of combined resection for these cases.
Of the various involved structures, the main bronchus
was related to the best prognosis, as previously reported.3,20
Only 1 patient of those with bronchogenic carcinoma,
invasion less than 2 cm from the carina, and had no
lymph node metastasis died during the follow-up period.
Thus, the T3 criterion of tumor in the main bronchus less
than 2 cm distal to the carina could be re-evaluated.
Lung cancer with diaphragmatic invasion is currently
categorized as a T3 tumor; however, it has been suggested
that the disease should be reclassified as T4 because of its
poorer prognosis.21,22 In the 7th edition of the AJCC
Cancer Staging Handbook states that the classification of
diaphragmatic invasion might need to be re-evaluated in
the future as more survival data become available.23 Despite
these arguments, the present study has demonstrated that
patients with lung cancer and pathologically proven dia-
phragmatic invasion and N0 disease had similar prognoses
compared with other T3N0 cases. Although only 20 cases
were in the present study, limiting the conclusions that
can be drawn, it is possible that diaphragmatic invasion is
suitable for T3 classification because of the improvements
in perioperative factors.436 The Journal of Thoracic and Cardiovascular SurgThe prognosis of patients with T3 tumors involving the
pericardium was relatively good, regardless of nodal status.
Sakakura and colleagues3 reported the 5-year survival rate
of 14 patients who underwent resection of tumor invading
the pericardium, including 5 patients with N2 disease,
was 21.4%. The current result could still be equivocal be-
cause the number of patients was small (n¼ 20) in our study
population, and only a few studies have addressed the prog-
nosis of those patients.
Our study had several limitations. This was a retrospec-
tive study, and the cases were accumulated from a large
number of institutions, which could have resulted in institu-
tional diversity in the surgical procedure and management
and the indications for perioperative therapies. In addition,
some information was lacking in the registry, such as the use
of postoperative radiotherapy and tumor differentiation. Fi-
nally, 18 patients had invasion in more than 1 structure. The
5-year survival rate and median survival time of that group
was 28.9% and 21months, respectively, worse than those of
the patients with involvement of a single structure. How-
ever, such overlapping occurred in a very small number of
patients and even included patients with 3 involved organs.
Therefore, we analyzed the prognostic factors for all pa-
tients with T3 invasive lung cancer.CONCLUSIONS
The modern 5-year survival rates of patients with T3
lung cancer involving any neighboring structures from the
present nationwide study were 40% to 55%. Our study
also provided additional valuable information. The current
pT3 group with involvement of various structures was
found to have a relatively uniform prognosis, although
more survival data should be collected for the next TNM
staging revision.References
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